⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

June 30, 2003Journal of Clinical Oncology

Maybe More Is Better

View at Publisher

Ask AI

Bookmark

Share

Abstract

Article Tools EDITORIALS Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.2003.93.115 Journal of Clinical Oncology - published online before print September 21, 2016 PMID: 12829661 Maybe More Is Better Tate ThigpenxTate ThigpenSearch for articles by this author Show More Division of Oncology, University of Mississippi Medical Center, Jackson, MS https://doi.org/10.1200/JCO.2003.93.115 First Page Full Text PDF Figures and Tables © 2003 by American Society of Clinical Oncology

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Tate Thigpen (2003) studied this question.

synapsesocial.com/papers/6a92cec1a0a82415c1a298ef https://doi.org/10.1200/jco.2003.93.115

View at Publisher

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Dose intensity analysis of chemotherapy regimens in ovarian carcinoma.Original Research · 1987 · 379 citations
2Importance of Multiagent Chemotherapy Regimens in Ovarian Carcinoma: Dose Intensity AnalysisMeta-Analysis · 1993 · 87 citations
3Assessment of dose-intensive therapy in suboptimally debulked ovarian cancer: a Gynecologic Oncology Group study.Prognostic Study · 1995 · 213 citations
4Responses to second-line cisplatin-based intraperitoneal therapy in ovarian cancer: influence of a prior response to intravenous cisplatin.Retrospective Study · 1991 · 191 citations
5Cyclophosphamide and Cisplatin Compared with Paclitaxel and Cisplatin in Patients with Stage III and Stage IV Ovarian Cancer1996 · 2,797 citations

Randomized Intergroup Trial of Cisplatin-Paclitaxel Versus Cisplatin-Cyclophosphamide in Women With Advanced Epithelial Ovarian Cancer: Three-Year Results2000
Phase III Randomized Study of Cisplatin Versus Paclitaxel Versus Cisplatin and Paclitaxel in Patients With Suboptimal Stage III or IV Ovarian Cancer: A Gynecologic Oncology Group Study2000
Phase III Trial of Standard-Dose Intravenous Cisplatin Plus Paclitaxel Versus Moderately High-Dose Carboplatin Followed by Intravenous Paclitaxel and Intraperitoneal Cisplatin in Small-Volume Stage III Ovarian Carcinoma: An Intergroup Study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group2001
Art as a Shared Space: Tracing the Unseen Through a Body MapJournal of Clinical Oncology · 2026
PARP Inhibitors in the Management of Ovarian Cancer: ASCO Living Guideline, Version 2026.1.0Journal of Clinical Oncology · 2026

More from Journal of Clinical Oncology